Evidence map›Paper›PMID 33787012›Full record

ArticleEMBO molecular medicine2021

High levels of circulating osteopontin in inflammatory lung disease regardless of Sars-CoV-2 infection.

Giuseppe Cappellano, Hugo Abreu, Davide Raineri, Lorenza Scotti, Luigi Castello, Rosanna Vaschetto, Annalisa Chiocchetti

Erratum issuedOpen access · goldAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Giuseppe CappellanoDepartment of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.ORCID 0000-0001-5193-4688
Hugo AbreuDepartment of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.
Davide RaineriDepartment of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.
Lorenza ScottiDepartment of Translational Medicine, Universita' del Piemonte Orientale, Novara, Italy.
Luigi CastelloDepartment of Translational Medicine, Universita' del Piemonte Orientale, Novara, Italy.
Rosanna VaschettoDepartment of Translational Medicine, Universita' del Piemonte Orientale, Novara, Italy.
Annalisa ChiocchettiDepartment of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Fondazione Cariplo (Cariplo Foundation) Fondazione Cariplo 2019-3277H2020 Excellent Science (H2020 Priority Excellent Science) No. 953121-project FLAMIN-GOMinistero dell'Istruzione, dell'Università e della Ricerca (MIUR)
6 · The paper itself

Abstract

This study independently confirms increased levels of osteopontin in COVID-19 patients but also suggests that osteopontin cannot be used as a biomarker of SARS-CoV-2 infection, as elevated levels of circulating osteopontin are found in inflammatory lung disease regardless of SARS-CoV-2 infection.

Indexed as

COVID-19SARS-CoV-2Energy MetabolismHumansMitochondriaMonocytesOsteopontinOsteopontin

Identifiers

PMID33787012
PMCPMC8103078
OpenAlexW4200197241

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.